When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment.
Ultrasensitive immunoassays offer new opportunities to address these challenges. In this webinar, discover how high-sensitivity assay technologies and tailored assay development strategies can help quantify low-abundance proteins and generate insights from challenging biological samples.
Drawing on examples from custom assay development, we will explore how antibody selection, platform choice and assay optimisation influence analytical sensitivity and performance. You will learn how transferring established antibody pairs between platforms and optimising existing assays can offer practical routes to improving sensitivity, where technically feasible.
We will also examine key considerations for generating reliable data from clinical samples, including matrix effects, specificity and reproducibility, and why early assay development planning can help identify analytical challenges before they affect downstream studies.
Participants will learn how to:
  • Assess options for measuring low-abundance biomarkers in challenging biological samples.
  • Understand how antibody selection, platform capabilities and assay optimisation influence sensitivity and assay performance.
  • Explore strategies for improving the sensitivity of existing assays or adapting established antibody pairs to alternative platforms.
  • Identify critical considerations for reliable clinical sample analysis and early assay development planning.
  • Evaluate trade-offs between sensitivity, throughput, robustness and cost when selecting an immunoassay approach for your research or development programme.
A live Q&A follows the presentation.
Register now!